Literature DB >> 24578044

Complement-dependent cytotoxicity (CDC) to detect Anti-HLA antibodies: old but gold.

Patrícia Keiko Saito1, Roger Haruki Yamakawa, Lucieni Christina Marques da Silva Pereira, Waldir Veríssimo da Silva, Sueli Donizete Borelli.   

Abstract

BACKGROUND: The criterion (gold) standard to detect anti-human leukocyte antigen (HLA) antibodies is the complement-dependent cytotoxicity (CDC) assay. Recently, more sensitive methods have been used for the same purpose.
METHODS: This study analyzed 70 serum samples of patients with end-stage renal disease using CDC, CDC with the addition of anti-human globulin (CDC-AHG), CDC with the addition of dithiothreitol (CDC-DTT), and the recent solid-phase immunoassay (SPI; Labscreen PRA) to detect anti-HLA antibodies.
RESULTS: Mean percent panel reactive antibodies (PRA) detected by SPI was 37.5% (±34.2) higher than the values detected by the other methods. Comparative analyses revealed significant difference between CDC and CDC-AHG, and between CDC and SPI (P < 0.0001), but not between CDC-AHG and SPI (P = 0.8026).
CONCLUSION: Although the CDC-AHG method is "old," its performance to detect anti-HLA antibodies in the samples analyzed was comparable to the SPI in the evaluation of percent class I PRA.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  CDC; HLA; alloantibodies; end-stage renal disease; panel reactive antibodies; solid-phase immunoassay; transplantation

Mesh:

Substances:

Year:  2014        PMID: 24578044      PMCID: PMC6807399          DOI: 10.1002/jcla.21678

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  17 in total

1.  Benefits of new methods for detection of anti-HLA class I antibodies.

Authors:  V Dubois; G Perrat; A Assaqa; J Carrie; Y Primard; L Gebuhrer
Journal:  Transplant Proc       Date:  2002-05       Impact factor: 1.066

2.  The global role of kidney transplantation.

Authors:  Guillermo Garcia Garcia; Paul Harden; Jeremy Chapman
Journal:  Kidney Blood Press Res       Date:  2012-02-20       Impact factor: 2.687

3.  The clinical importance of flow cytometry crossmatch in the context of CDC crossmatch results.

Authors:  R J Graff; P M Buchanan; N Dzebisashvili; M A Schnitzler; J Tuttle-Newhall; H Xiao; E Schadde; A Gheorghian; K L Lentine
Journal:  Transplant Proc       Date:  2010-11       Impact factor: 1.066

4.  Luminex technology for anti-HLA antibody screening: evaluation of performance and of impact on laboratory routine.

Authors:  Maria Bernadette Colombo; Simone Elisabeth Haworth; Francesca Poli; Angela Nocco; Giuseppe Puglisi; Annalisa Innocente; Marta Serafini; Piergiorgio Messa; Mario Scalamogna
Journal:  Cytometry B Clin Cytom       Date:  2007-11       Impact factor: 3.058

5.  A method to increase the sensitivity of the lymphocyte microcytotoxicity test.

Authors:  D Nelken; I Cohen; I Furcaig
Journal:  Transplantation       Date:  1970-10       Impact factor: 4.939

6.  Significance of the positive crossmatch test in kidney transplantation.

Authors:  R Patel; P I Terasaki
Journal:  N Engl J Med       Date:  1969-04-03       Impact factor: 91.245

Review 7.  Comparison of the established standard complement-dependent cytotoxicity and flow cytometric crossmatch assays with a novel ELISA-based HLA crossmatch procedure.

Authors:  W W Altermann; B Seliger; S Sel; D Wendt; G Schlaf
Journal:  Histol Histopathol       Date:  2006-10       Impact factor: 2.303

Review 8.  Intravenous immunoglobulin induction treatment in flow cytometry cross-match-positive kidney transplant recipients.

Authors:  Enver Akalin; Jonathan S Bromberg
Journal:  Hum Immunol       Date:  2005-04       Impact factor: 2.850

Review 9.  Mature wines are better: CDC as the leading method to define highly sensitized patients.

Authors:  Ilias I N Doxiadis; Dave Roelen; Frans H J Claas
Journal:  Curr Opin Organ Transplant       Date:  2010-12       Impact factor: 2.640

10.  Histocompatibility testing for highly sensitized transplant candidates.

Authors:  S L Saidman
Journal:  Transplant Proc       Date:  2007-04       Impact factor: 1.066

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.